Comparison of Semaglutide, Tirzepatide, and Retatrutide

For Canadians comparing today’s leading incretin-based weight loss drugs, the practical choice is usually between semaglutide and tirzepatide, because both have Canadian-authorized obesity brands. Retatrutide is different: it is a promising investigational triple-receptor medicine, but it is not yet a routine prescription option in Canada. This comparison explains how the three medications differ, where “semaglutide vs tirzepatide” really matters, and what to discuss with a Canadian healthcare professional before making a decision.

Last updated: August 2026. Educational information only — not medical advice.

Key takeaways

• Semaglutide and tirzepatide are the only two you can actually be prescribed in Canada today. Retatrutide is investigational everywhere.
• Tirzepatide outperformed semaglutide head-to-head. SURMOUNT-5 reported an average weight change of -20.2% versus -13.7% at 72 weeks in 751 adults with obesity.
• Retatrutide has the highest trial numbers so far — an average of 28.3% at the 12 mg dose over 80 weeks in Phase 3 — but no head-to-head data and no approval.
• Retatrutide is not expected to be filed for regulatory approval until 2027, so a Canadian launch would come later still.
• Side-effect profiles overlap. Gastrointestinal effects dominate for all three, and contraindications are similar across the class.
• Unauthorized online “research peptide” versions are not equivalent to a prescription product dispensed by a licensed Canadian pharmacy.

Semaglutide vs tirzepatide vs retatrutide at a glance

Which option fits which Canadian patient?

The simplest answer is this: semaglutide may fit people who want the most established single GLP-1 pathway option, tirzepatide may fit adults looking for a dual-pathway option authorized for chronic weight management in Canada, and retatrutide is best understood as a future candidate rather than a current treatment choice. Canadian drug regulators identify semaglutide products such as Ozempic, Rybelsus, and Wegovy, and tirzepatide products such as Mounjaro and Zepbound, as prescription drugs authorized to treat type 2 diabetes and obesity; regulators have also warned Canadians not to buy unauthorized GLP-1 products online or from unlicensed sellers.

A quick decision summary:

• Choose semaglutide to discuss first if: you and your clinician prefer a GLP-1 receptor agonist with an obesity-specific Canadian brand option, a familiar dosing pathway, and a large base of clinical and real-world experience.
• Choose tirzepatide to discuss first if: you want to consider a dual GIP and GLP-1 receptor agonist for adult chronic weight management, especially if your clinician believes a broader incretin mechanism may suit your health profile.
• Do not choose retatrutide outside a legitimate clinical trial: retatrutide is an investigational GIP, GLP-1, and glucagon triple hormone receptor agonist being studied in Phase 3 trials and is not currently a standard prescription option in Canada.

This page is educational and not personal medical advice. In Canada, the right decision depends on your BMI, weight-related conditions, diabetes status, medication history, pregnancy plans, side-effect risk, benefits coverage, availability at licensed pharmacies, and the goals you set with a physician, nurse practitioner, pharmacist, endocrinologist, or obesity medicine clinician.

The three medications use related but different receptor strategies

Semaglutide, tirzepatide, and retatrutide are often grouped together because they all affect incretin biology, appetite regulation, and metabolic health. The key difference is how many hormonal receptor pathways each medicine is designed to activate. That difference matters because it can influence weight-loss potential, tolerability, blood-glucose effects, future research questions, and how comfortable clinicians are with long-term use.

Semaglutide is a GLP-1 receptor agonist. Wegovy, the obesity-focused semaglutide brand, is authorized in Canada as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related comorbidity.

Tirzepatide activates both GIP and GLP-1 receptors. The Canadian product monograph for Zepbound describes tirzepatide as a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, and its obesity indication is for once-weekly use alongside reduced-calorie diet and increased physical activity in eligible adults.

Retatrutide is being studied as a triple agonist of GIP, GLP-1, and glucagon receptors. A Phase 2 obesity trial published in the New England Journal of Medicine described retatrutide as a GIP–GLP-1–glucagon receptor triple agonist. (nejm.org)

Semaglutide vs tirzepatide is the current practical comparison

For most Canadian patients searching for weight loss drugs, the immediate comparison is not all three drugs equally. It is semaglutide vs tirzepatide, with retatrutide kept in mind as pipeline context. Semaglutide and tirzepatide have Canadian prescription pathways, product monographs, pharmacy dispensing rules, and safety information that clinicians can use today; retatrutide does not yet occupy the same practical category.

Compare them by the criteria that actually affect treatment decisions:

• Canadian regulatory status
  • Semaglutide has obesity-specific authorization through Wegovy. Depending on current listings and availability, there may also be generic semaglutide products authorized in Canada—your clinician or pharmacist can confirm what is actually available for your indication.
  • Tirzepatide has obesity-specific authorization through Zepbound for adult chronic weight management, with once-weekly dosing and prescriber-selected maintenance doses.
  • Retatrutide remains investigational; early results have been published and later-stage results have been announced, but it is not yet authorized for routine prescribing in Canada.
• Mechanism
  • Semaglutide focuses on GLP-1 receptor activity.
  • Tirzepatide adds GIP receptor activity to GLP-1 receptor activity.
  • Retatrutide adds glucagon receptor activity to GIP and GLP-1 activity, which is why it is often discussed as a next-generation or triple agonist option. (nejm.org)
• Best current use case
  • Semaglutide is a current option to discuss for chronic weight management when a GLP-1 agonist is clinically appropriate.
  • Tirzepatide is a current option to discuss when an adult patient and clinician want to consider dual incretin therapy for chronic weight management.
  • Retatrutide is a research-stage option to watch, not a product to purchase from online sellers or “peptide” vendors.
• Comfort and certainty
  • Semaglutide has the advantage of longer mainstream use and broad clinician familiarity.
  • Tirzepatide has rapidly expanding obesity and metabolic data, but the choice still depends on individual contraindications, adverse effects, and access.
  • Retatrutide has exciting trial results, but less long-term post-approval experience because it is not yet approved.

Which option is available in Canada right now?

Semaglutide and tirzepatide are the available prescription categories to discuss for obesity treatment in Canada; retatrutide is not a normal Canadian prescription option as of August 2026. If you need to verify whether a specific product is authorized and marketed, check the official Canadian listings (for example, the Drug Product Database) or ask a pharmacist to confirm the DIN and current status.

The Canadian availability picture looks like this:

• Semaglutide
  • Obesity brand: Wegovy.
  • Diabetes brands include Ozempic and Rybelsus, but a diabetes indication is not the same as an obesity indication.
  • There may be generic semaglutide products authorized for specific uses; availability and pricing can vary, so confirm with a licensed Canadian pharmacy.
• Tirzepatide
  • Obesity brand: Zepbound.
  • Diabetes brand: Mounjaro.
  • The Canadian product monograph outlines indications and use criteria for chronic weight management in adults meeting BMI and comorbidity thresholds.
• Retatrutide
  • No routine Canadian prescription brand is available for obesity treatment. Our guide to retatrutide availability in Canada tracks the current status.
  • Current legitimate access is through properly authorized clinical research, where applicable.
  • Products sold online as “retatrutide” for personal use should be treated as high risk because they are not authorized Canadian prescription products.

Effectiveness depends on more than the headline weight-loss number

Clinical trial averages can be helpful, but they do not tell you what will happen to one person. Obesity Canada emphasizes that individual response to pharmacotherapy is variable and that medication choice should consider health conditions, side effects, formulation, dosing frequency, interactions, and cost. (obesitycanada.ca)

For semaglutide, Canadian regulatory materials and the Wegovy product information describe authorization based on Phase 3 randomized trials where semaglutide produced significantly greater weight loss than placebo, alongside improvements in cardiometabolic endpoints. Dose escalation is commonly used to reduce the incidence or severity of gastrointestinal side effects.

For tirzepatide, Canadian product information for Zepbound describes its chronic weight management program in adults with obesity or overweight plus weight-related comorbidity, including SURMOUNT studies using reduced-calorie diet and physical activity counselling. It lists gastrointestinal reactions such as nausea, diarrhea, constipation, and vomiting among the most frequently reported adverse reactions in weight management trials.

For retatrutide, the headline data are attention-grabbing, but the practical interpretation is cautious. Early efficacy and safety results were published in peer-reviewed research and Phase 3 results have now been reported, yet retatrutide remains investigational and is not an authorized obesity medication in Canada or anywhere else. Its developer has indicated it does not expect to submit the drug for regulatory approval until 2027, so a Canadian prescription pathway is still some way off.

What the head-to-head and latest trial data show

SURMOUNT-5 is the only large randomized trial to compare tirzepatide and semaglutide directly. Among 751 adults with obesity and without type 2 diabetes, average weight change at 72 weeks was -20.2% with tirzepatide (about 22.8 kg) versus -13.7% with semaglutide (about 15.0 kg), and waist circumference fell 18.4 cm versus 13.0 cm.

For retatrutide, Phase 3 results reported in May 2026 from the TRIUMPH-1 trial showed average weight loss of 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg after 80 weeks, with participants who had a baseline BMI of 35 or higher averaging 30.3% after 104 weeks on the 12 mg dose. Because retatrutide has never been compared head-to-head with tirzepatide, these figures cannot be treated as proof that one is stronger than the other in the same patients.

Side effects and safety risks shape the decision

These medications are not cosmetic shortcuts. They are prescription therapies used for medical conditions, and they require screening, monitoring, and a plan for side effects. Canadian health authorities have warned that known GLP-1 product risks can include severe gastrointestinal problems, pancreatitis, worsening kidney injury, and low blood sugar, particularly when combined with some other medications. For the investigational triple agonist specifically, see our breakdown of retatrutide side effects and clinical-trial data.

The comparison is not simply “which drug is strongest?” It is “which option offers a reasonable balance of benefit, tolerability, safety, and access for this specific patient?” That is why a person with diabetes, gallbladder disease history, severe gastrointestinal symptoms, kidney concerns, retinopathy risk, pregnancy plans, or multiple medications needs a careful clinical review before starting or switching.

Safety considerations to discuss in Canada include:

• Gastrointestinal tolerance: nausea, vomiting, diarrhea, constipation, reflux, abdominal pain, and dehydration risk can affect adherence and dose escalation.
• Blood sugar management: people using insulin or sulfonylureas may need closer monitoring because incretin-based therapies can increase hypoglycemia risk when combined with glucose-lowering drugs.
• Contraindications and warnings: for example, tirzepatide products for weight management are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and during pregnancy; similar class-specific concerns should be reviewed for each medication’s Canadian product monograph.
• Mental health monitoring: some product labels and Canadian guidance discuss monitoring mood changes or suicidal thoughts with weight-management medications.
• Nutrition and lean mass: rapid appetite reduction can make protein intake, resistance training, micronutrients, and follow-up important.

Which option is easier to access and afford?

In Canada, access is often decided by more than authorization alone. A medication can be approved but still difficult to obtain because of pharmacy supply, provincial formulary rules, private insurance criteria, prior authorization, prescriber availability, or out-of-pocket cost. Even when generics become available, individual prices and coverage can still vary by province, plan, pharmacy, and patient eligibility.

Think through access in this order:

1. Confirm the correct indication. Wegovy and Zepbound are obesity management brands; Ozempic, Rybelsus, and Mounjaro may be associated with diabetes indications, depending on the product and prescription context.
2. Check your benefits booklet or insurer portal. Many private plans require a special authorization form, BMI documentation, comorbidity information, previous therapy history, or renewal evidence.
3. Ask the pharmacy about supply before you start. A medication that cannot be refilled consistently can create interruptions, dose confusion, and frustration.
4. Avoid unauthorized online sellers. Canadian health authorities and provincial regulators advise consumers to obtain prescription drugs only through licensed providers and pharmacies; counterfeit or unauthorized products may contain the wrong ingredient amount, contaminants, or unknown ingredients.
5. Plan for long-term treatment. Obesity Canada notes that weight-management medications are intended as part of a long-term strategy and that stopping can lead to weight regain and loss of benefits. (obesitycanada.ca)

Retatrutide is promising, but it should not drive today’s prescription decision

Retatrutide deserves attention because it is designed to activate three receptor pathways rather than one or two. Early and late-stage studies suggest it may become an important future obesity medication, particularly for people with obesity-related complications. But “future option” is not the same as “safe to buy now.”

Canadian patients should be especially cautious with online “research peptide” marketing. If a product is not authorized in Canada, lacks a DIN, bypasses a licensed pharmacy, or is promoted through social media with dramatic before-and-after claims, it should not be treated as equivalent to a prescription medication. Unauthorized injectable products can also carry contamination and sterility risks.

If you want the underlying chemistry, our explainer on what retatrutide is made from covers its structure and ingredients.

A practical way to view retatrutide:

• Worth watching: yes, because Phase 3 results and regulatory submissions may change the obesity treatment landscape.
• Worth asking your clinician about: yes, especially if you are interested in clinical trials or future treatment planning.
• Worth buying online without a prescription: no.
• Equivalent to semaglutide or tirzepatide today: no, because it does not yet have the same Canadian approval, prescribing, pharmacy, and post-market framework.

Decision summary for Canadian patients

If you need a current, regulated obesity medication discussion in Canada, start with semaglutide and tirzepatide. Semaglutide is the established GLP-1 agonist option, while tirzepatide is the dual GIP and GLP-1 agonist option with a Canadian obesity brand. Retatrutide is a high-interest investigational medicine, but it belongs in the “watch closely” category until regulators review and authorize it.

Use this final checklist before choosing a path:

• Medical fit: Do you meet the Canadian product indication criteria for chronic weight management?
• Comorbidities: Do you have type 2 diabetes, sleep apnea, hypertension, dyslipidemia, cardiovascular disease, fatty liver disease, or other obesity-related conditions that may affect selection?
• Safety: Do you have contraindications, pregnancy plans, severe gastrointestinal disease, pancreatitis history, kidney concerns, or medications that increase hypoglycemia risk?
• Practical access: Is the medication available at a licensed Canadian pharmacy, covered by your plan, and likely refillable?
• Long-term plan: Are nutrition, physical activity, behavioural support, monitoring, and maintenance built into the treatment plan?
• Product legitimacy: Does the medication have a DIN, come from a licensed pharmacy, and match your prescription exactly?

For many Canadians, the best next step is not picking a drug name from an online comparison. It is booking a conversation with a qualified healthcare professional, bringing your medication list and insurance details, and asking which option fits your health goals, risks, and real-world access. That approach keeps the comparison grounded: semaglutide and tirzepatide are today’s practical choices, while retatrutide remains a future possibility to follow carefully.

Frequently asked questions

What is the difference between semaglutide, tirzepatide and retatrutide?

The difference is how many hormone receptors each drug activates. Semaglutide is a single agonist that targets GLP-1. Tirzepatide is a dual agonist that targets GIP and GLP-1. Retatrutide is a triple agonist that targets GIP, GLP-1 and the glucagon receptor. More pathways has meant greater average weight loss in trials, but also less long-term safety data.

Which is better for weight loss, semaglutide or tirzepatide?

Tirzepatide produced more weight loss in the only large head-to-head trial. SURMOUNT-5 randomized 751 adults with obesity and without type 2 diabetes and reported an average weight change of -20.2% with tirzepatide versus -13.7% with semaglutide at 72 weeks. Individual results vary widely, and tolerability, cost, coverage and medical history still decide which is appropriate for a given patient.

How much weight loss has retatrutide produced in trials?

In the Phase 3 TRIUMPH-1 results reported in May 2026, adults with obesity lost an average of 19.0% of body weight at the 4 mg dose, 25.9% at 9 mg and 28.3% at 12 mg after 80 weeks. An earlier Phase 2 trial in the New England Journal of Medicine reported roughly 24% at 48 weeks. These are trial averages, not individual guarantees.

Is retatrutide approved in Canada?

No. Retatrutide is not authorized in Canada, and it is not approved in any other major market as of August 2026. Its developer has said it does not expect to file the drug for regulatory approval until 2027. Anything sold today as retatrutide is not an approved prescription medicine and has not been assessed by a drug regulator.

When will retatrutide be available in Canada?

There is no confirmed Canadian launch date. With a regulatory filing expected in 2027, a Canadian authorization and pharmacy launch would follow only after that review completes, which typically takes about a year or more. Timelines shift, so treat any specific date you see quoted online as speculation rather than fact.

Is retatrutide stronger than tirzepatide?

Trial averages point that way, but the two have never been compared head-to-head. Cross-trial comparisons are unreliable because patient populations, baseline weights, trial lengths and protocols differ. Retatrutide also has far less long-term safety and real-world data, which matters as much as peak efficacy when a medicine is taken for years.

Do you need a prescription for semaglutide or tirzepatide in Canada?

Yes. Both are prescription-only medicines in Canada and must be dispensed by a licensed pharmacy against a valid prescription. A prescriber assesses BMI, weight-related conditions, contraindications and other medications before starting treatment, then supervises dose escalation and monitors side effects during ongoing therapy.

Are online research-peptide versions of these drugs safe to use?

No, not for human use. Products sold online as research chemicals are not authorized medicines, carry no DIN and are not dispensed by a licensed pharmacy. They can be mislabelled, under-dosed or over-dosed, non-sterile or contaminated. Canadian regulators have repeatedly warned consumers against buying unauthorized injectable weight-loss products online.

What are the most common side effects of these medications?

Gastrointestinal effects are the most common for all three: nausea, vomiting, diarrhea, constipation and abdominal pain. They are usually worst during dose escalation and often ease with time. Less common but more serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and low blood sugar when combined with insulin or sulfonylureas.

Who should not take semaglutide or tirzepatide?

These medicines are contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and during pregnancy. Extra caution or specialist input is needed with a history of pancreatitis, severe gastrointestinal disease, gallbladder disease, significant kidney impairment, diabetic retinopathy or an eating disorder. Review the Canadian product monograph with a prescriber.

Can you switch between semaglutide and tirzepatide?

Yes, switching is possible, but it should be prescriber-directed. The doses are not interchangeable because the two drugs use different units and escalation schedules, so a clinician restarts titration on the new medication rather than converting a dose. Common reasons to switch include a weight plateau, side effects, supply problems or a change in insurance coverage.

Do you have to stay on these medications long term?

Obesity is treated as a chronic condition, so these medicines are intended for long-term use. Obesity Canada notes that stopping pharmacotherapy commonly leads to weight regain and loss of the metabolic benefits. Some people taper with close support, but discontinuation should be planned with a clinician alongside nutrition, activity and behavioural strategies.

Do semaglutide, tirzepatide and retatrutide cause muscle loss?

A meaningful share of the weight lost is lean mass, as happens with any substantial weight loss rather than being unique to these drugs. Adequate protein intake, resistance training, slower dose escalation and follow-up body composition checks are the usual strategies clinicians use to protect muscle during treatment.

Which option is better if you also have type 2 diabetes?

Both semaglutide and tirzepatide have diabetes-indicated products in Canada: Ozempic and Rybelsus for semaglutide, and Mounjaro for tirzepatide. The choice depends on A1C targets, cardiovascular and kidney history, other glucose-lowering medications, injection preference and coverage. Retatrutide is still being studied in diabetes and is not an option outside a clinical trial.

How much do semaglutide and tirzepatide cost in Canada?

Out-of-pocket cost for the obesity-indicated brands typically runs into the hundreds of dollars per month, and public drug plans rarely cover weight-management indications. Private plans often require special authorization with BMI and comorbidity documentation. Ask the pharmacy for the current cash price and your insurer for the exact criteria before starting.

What does triple agonist mean?

A triple agonist activates three hormone receptors at once. Retatrutide targets GIP and GLP-1, which reduce appetite and improve glucose control, plus the glucagon receptor, which is thought to increase energy expenditure. That added glucagon activity is the main reason retatrutide has produced larger average weight loss than single or dual agonists in trials.